The 2026 Healthtech Messaging Index
Formation Bio
formation.bio·scored September 1, 2026
17/38
Invisible
The page is doing some work, but the story isn't landing fast enough. Buyers and AI are both left guessing what makes Formation Bio different.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for Tech-enabled clinical-stage drug development and licensing partner, it named:
Buyer we put in the prompt: Business development or licensing executive at a pharma company, biotech, or university technology transfer office looking to out-license or co-develop clinical-stage drug assets. Both the buyer and the category were inferred from Formation Bio’s homepage alone. The model had no web access.
Formation Bio was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "Tech-enabled clinical-stage drug development and licensing partner", and described you accurately: "Formation Bio (formerly TriNetX) is an AI-driven pharma company that in-licenses or acquires clinical-stage assets from pharma and biotech companies and uses technology to accelerate and reduce the cost of clinical development.". Your positioning is landing with the machines.
Overall assessment
Formation Bio's single biggest strength is its clear structural problem framing ... 'the drug development bottleneck' is a real, named insight that separates it from pure capability-speak. The single biggest gap is the near-total absence of social proof, concrete outcome metrics, and cost-of-inaction stakes: no partner names, no before/after timelines, and no answer to 'what does a partner lose by not working with us?' ... which means the page reads like a pitch deck introduction rather than a conversion-ready homepage.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
07Cost of Inaction
“No explicit cost-of-inaction language anywhere on the page ... no lost revenue, failed programs, or patient harm quantified.”
The page describes the bottleneck conceptually but never names what a pharma or biotech partner loses in dollars, time, or competitive position by not changing.
All 19 signals, scored 0 to 2.
Total 17/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“The pharma company of the future. Our mission is to bring new treatments to patients faster and more efficiently.”
The hero communicates direction and general mission but requires domain knowledge to decode ... a non-pharma stranger won't understand who the buyer/partner is or the specific problem without reading further.
- 1
02Rebellion / Movement
“The existing drug development ecosystem can't keep up with the pace of scientific discovery.”
There is a named status quo being pushed against ... a slow, inefficient development ecosystem ... but no named enemy, no confrontational positioning, and no manifesto-level conviction behind the rebellion.
- 1
03Owned Language & Category
“tech-driven, AI-native pharma company" and "radical efficiency throughout the drug development lifecycle”
"AI-native" and "radical efficiency" hint at a frame but neither term is defined, owned, or named as a proprietary category that AI would quote back exclusively to Formation Bio.
- 1
04ICP Clarity
“Formation Bio acquires clinical-stage drugs from pharma, universities, and biotech”
Partner types are named mid-page but roles, company size, and stage of partner are not surfaced above the fold, making instant self-identification difficult.
- 1
05Problem Leadership
“The drug development bottleneck" and "drug development costs have exponentially increased”
The problem is named and explained but it appears well below the fold, after company-centric hero copy, so the page does not lead with the buyer's problem.
- 1
06Solution Clarity
“acquires clinical-stage drugs from pharma, universities, and biotech and develops them faster and more efficiently by leveraging our proprietary tech-driven drug development platform”
A one-sentence explanation exists but it is buried mid-page and uses vague platform language rather than a crisp, memorable mechanism a visitor could repeat immediately.
- 0
07Cost of Inactionweakest
“No explicit cost-of-inaction language anywhere on the page ... no lost revenue, failed programs, or patient harm quantified.”
The page describes the bottleneck conceptually but never names what a pharma or biotech partner loses in dollars, time, or competitive position by not changing.
- 1
08Promised Land
“reaching inflection points earlier than industry norms while also accelerating access to new potential treatments for patients”
An 'after' state is implied ... earlier inflection points, faster patient access ... but it is not painted with specific, concrete outcomes that make it vivid or measurable.
Trust Signal
4 signals
- 1
09Proof & Evidence
“Our team and advisors have collectively worked on 45+ approved drugs”
One concrete number exists (45+ approved drugs) but there are no before/after deltas, timeline comparisons, or outcome-specific metrics tied to Formation Bio's own programs.
- 0
10Social Proof
“No customer logos, named testimonials, case studies, or partner quotes anywhere on the page.”
Social proof is entirely absent ... no partner names, no quotes with titles, no deal announcements presented as endorsements.
- 1
11Authority & Credibility
“Mike Ehlers joins Formation Bio as Chief Scientific Officer and Head of R&D" and "45+ approved drugs”
Credibility signals exist (senior hire announcement, collective drug approvals) but founder credentials, original research, or frameworks are not demonstrated on the homepage itself.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, CROs, or 'do nothing' option anywhere on the page.”
The page makes no acknowledgment of what partners could do instead, leaving a trust gap by ignoring the buyer's real decision landscape.
AI Signal
6 signals
- 1
13Customer Focus
“striving to meet critical unmet patient need" and "enabling us and our partners to realize greater value per drug program”
The page oscillates between company capabilities and partner/patient outcomes but tilts toward describing Formation Bio's platform rather than centering the partner's transformation.
- 1
14AI-Parmesan Index
“tech-driven, AI-native platform" and "proprietary tech-driven drug development platform”
AI-native is claimed repeatedly but no mechanism, model, or specific AI application is described, making it closer to AI-parmesan sprinkling than substantive AI specificity.
- 1
15LLM Quotability
“The existing drug development ecosystem can't keep up with the pace of scientific discovery.”
This sentence is clean and declarative but most page copy is too vague or aspirational to be lifted by an LLM as a specific, citable recommendation for Formation Bio over alternatives.
- 1
16Copyright Freshness
“Mike Ehlers joins Formation Bio as Chief Scientific Officer" appears as a recent news banner but no dates on blog posts or copyright year are visible in the scraped content.”
One recent hire announcement signals some recency but without visible dated case studies, publication dates, or a copyright year in the scraped content, freshness signals are weak.
- 1
17Entity Distinctiveness
“tech-driven, AI-native pharma company" that "acquires clinical-stage drugs from pharma, universities, and biotech”
The acquire-and-develop model is somewhat distinctive but the language (AI-native, tech-driven, faster and more efficiently) is shared by many biotech platforms, so an AI could confuse this with competitors like Recursion or Eikon Therapeutics.
- 2
18AI Recommendation Check
“AI described you as: "Formation Bio (formerly TriNetX) is an AI-driven pharma company that in-licenses or acquires clinical-stage assets from pharma and biotech companies and uses technology to accelerate and reduce the cost of clinical development.”
AI named you when asked who it recommends for "Tech-enabled clinical-stage drug development and licensing partner", and described you accurately: "Formation Bio (formerly TriNetX) is an AI-driven pharma company that in-licenses or acquires clinical-stage assets from pharma and biotech companies and uses technology to accelerate and reduce the cost of clinical development.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“Partner With Us" CTA and "Contact Us" link exist but no numbered process or soft secondary CTA is present.”
There is a primary CTA (Contact Us) and a soft Partner With Us prompt, but no visible numbered steps or process that connects the journey, so path clarity is incomplete.
Keep the lead
AI already names Formation Bio. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Formation Bio the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.